Biotech news
Americas
Mexican patent examiners usually reject patents directed to human embryonic stem cells, but applications filed after 2008 may have a greater chance of being approved, as Jasmin Maqueda of Becerril, Coca & Becerril describes. 16 June 2015
Americas
The inter partes review system was set up as a cheaper way of invalidating patents than litigation. Given the high success rate, and the large number of ‘patent trolls’ involved, is it likely that troll activity will be dampened? Steve Coyle, Leslie-Anne Maxwell and Chad Dever of Cantor Colburn investigate. 16 June 2015
Americas
The pharmaceutical and biotechnology industries are in “very good shape” and the so-called patent cliff is “firmly in the rear view mirror”, according to a report by life sciences market research company Evaluate. 16 June 2015
Americas
As far we know, the IP chapter in the proposed Trans-Pacific Partnership agreement contains provisions on modernising plant breeders’ rights, but not all the participating countries are currently on the same page, as LSIPR reports. 16 June 2015
Pharma
How will the OECD’s Modified Nexus Approach to innovator-friendly tax regimes such as the UK’s patent box affect the life sciences industry? LSIPR investigates. 16 June 2015
Americas
The antibiotics market could lose out for a decade due to inadequate research and development in the area, according to a report published by UK law firm Marks & Clerk today, June 16. 16 June 2015
Americas
US law firm White and Williams has hired George Xixis as a counsel to its Boston office. 12 June 2015
Americas
LSIPR picks five sessions IP professionals won’t want to miss at this year’s BIO International Convention in Philadelphia, from June 15 to 18. 11 June 2015
Americas
The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda. 10 June 2015
Americas
The US Court of Appeals for the Federal Circuit has heard oral arguments in Amgen v Sandoz, a case that should determine whether it is mandatory for biosimilar applicants to engage in the so-called patent dance. 8 June 2015